SCHEMBL21777235

SCHEMBL21777235

O=C(O)N(c1cscn1)S(=O)(=O)c1ccc(Cl)nc1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.47
TDP1 Q9NUW8 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
MAPT P10636 1/20 0.45
PTPN22 Q9Y2R2 1/20 0.38
NAPRT Q6XQN6 1/20 0.36
POLB P06746 1/20 0.35
GAA P10253 2/20 0.35
EGFR P00533 2/20 0.35
LMNA P02545 1/20 0.34
MAPK1 P28482 1/20 0.34
TRPM8 Q7Z2W7 1/20 0.33
GRM4 Q14833 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30045772 0.83 SMN1; SMN2 (0.42) ALDH1A1TDP1L3MBTL1SMN1; SMN2MEN1
SCHEMBL21783501 0.83 SMN1; SMN2 (0.42) ALDH1A1TDP1L3MBTL1SMN1; SMN2MEN1
SCHEMBL21777144 0.81 ALDH1A1 (0.46) ALDH1A1TDP1L3MBTL1MAPTPOLB
SCHEMBL21773513 0.79 ALDH1A1 (0.33) ALDH1A1TRPM8
SCHEMBL19613825 0.79 FLT1 (0.34) ALDH1A1SMN1; SMN2MEN1KMT2AMAPT
SCHEMBL20449230 0.78 TDP1 (0.37) TDP1MEN1KMT2AGAATRPM8
SCHEMBL26931067 0.75 ALDH1A1 (0.61) ALDH1A1TDP1L3MBTL1SMN1; SMN2MEN1
SCHEMBL19613603 0.72 SCN8A (0.37) LMNA
SCHEMBL20238354 0.72 ESR1 (0.36) MEN1KMT2AMAPTLMNATRPM8
SCHEMBL19617873 0.69 SCN8A (0.37) GRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11639351-B2 Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. 2023-05-02 US disclosed
EP-3844150-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS Xenon Pharmaceuticals Inc. (CA) 2021-07-07 EP disclosed
US-10981905-B2 Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2021-04-20 US disclosed
US-20200157089-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2020-05-21 US disclosed
WO-2020047323-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2020-03-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11639351-B2 Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents SCN1A, SCN2A, SCN2B ALDH1A1 2781/4885TDP1 2513/4885L3MBTL1 3143/4885
US-20200157089-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS SCN1A, SCN2A, SCN2B ALDH1A1 2781/4885TDP1 2513/4885L3MBTL1 3143/4885
US-10981905-B2 Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents SCN1A, SCN2A, SCN2B ALDH1A1 2781/4885TDP1 2513/4885L3MBTL1 3143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.